open access

Vol 7, No 4 (2011)
Review paper
Published online: 2011-10-26
Get Citation

Epidermal growth factor receptor (EGFR) inhibition on non-small-cell lung cancer treatment

Dariusz M. Kowalski, Maciej Krzakowski, Anna Janowicz-Żebrowska
Onkol. Prak. Klin 2011;7(4):177-182.

open access

Vol 7, No 4 (2011)
REVIEW ARTICLES
Published online: 2011-10-26

Abstract

Non small cell lung cancer (NSCLC) remains a significant clinical and social problem. In the last period there has been a steady increase a incidence in women and men. Results of surgical treatment, radiotherapy and chemotherapy have reached a plateau. Perspectives for pharmacological treatment of NSCLC determines understanding the molecular mechanisms responsible for tumor growth and resistance. The introduction of molecularly targeted drugs is an important step in the treatment of NSCLC. Targeted treatment includes the use of monoclonal antibodys, anti-angiogenic treatment and small molecule tyrosine kinase inhibitors. Identity of predictive factors plays a huge role for targeting treatment optimization.
Onkol. Prak. Klin. 2011; 7, 4: 177–182

Abstract

Non small cell lung cancer (NSCLC) remains a significant clinical and social problem. In the last period there has been a steady increase a incidence in women and men. Results of surgical treatment, radiotherapy and chemotherapy have reached a plateau. Perspectives for pharmacological treatment of NSCLC determines understanding the molecular mechanisms responsible for tumor growth and resistance. The introduction of molecularly targeted drugs is an important step in the treatment of NSCLC. Targeted treatment includes the use of monoclonal antibodys, anti-angiogenic treatment and small molecule tyrosine kinase inhibitors. Identity of predictive factors plays a huge role for targeting treatment optimization.
Onkol. Prak. Klin. 2011; 7, 4: 177–182
Get Citation

Keywords

non-small-cell lung cancer; target therapy; epidermal growth factor receptor; tyrosine kinase inhibitors; erlotinib; gefitinib; cetuximab

About this article
Title

Epidermal growth factor receptor (EGFR) inhibition on non-small-cell lung cancer treatment

Journal

Oncology in Clinical Practice

Issue

Vol 7, No 4 (2011)

Article type

Review paper

Pages

177-182

Published online

2011-10-26

Bibliographic record

Onkol. Prak. Klin 2011;7(4):177-182.

Keywords

non-small-cell lung cancer
target therapy
epidermal growth factor receptor
tyrosine kinase inhibitors
erlotinib
gefitinib
cetuximab

Authors

Dariusz M. Kowalski
Maciej Krzakowski
Anna Janowicz-Żebrowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl